Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Sci. Signal., 4 September 2012
Vol. 5, Issue 240, p. pe37
[DOI: 10.1126/scisignal.2003466]

PERSPECTIVES

Allosteric Regulation of Nucleotidyl Cyclases: An Emerging Pharmacological Target

Roland Seifert* and Kerstin Y. Beste

Institute of Pharmacology, Hannover Medical School, Hannover, Germany.

Abstract: Adenylyl cyclases (ACs) and guanylyl cyclases (GCs) produce the second messengers cyclic adenosine monophosphate and cyclic guanosine monophosphate, respectively. ACs and GCs are differentially regulated by intercellular signaling molecules and are implicated in various disease states, including cardiovascular diseases, aging, pain, and neuropsychiatric ailments. Hence, ACs and GCs constitute interesting drug targets. Because the catalytic sites of these enzymes are highly conserved, it is difficult to achieve isoform specificity. However, studies have provided evidence for the notion that regulatory allosteric domains in the vicinity of the catalytic site provide new opportunities for pharmacological intervention. Here, we summarize the current status of such research and discuss future directions in this exciting field.

* Corresponding author. E-mail: seifert.roland{at}mh-hannover.de

Citation: R. Seifert, K. Y. Beste, Allosteric Regulation of Nucleotidyl Cyclases: An Emerging Pharmacological Target. Sci. Signal. 5, pe37 (2012).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882